Clinical Sequencing

Management provided an update on reimbursement and new products in the works for whole-genome karyotyping, carrier screening, and oncology.

The firm reported Q4 2014 revenues of $36.8 million, up from $32.7 million in Q4 2013, but falling short of analysts' average estimate of $41.9 million.

Baylor's clinical exome enhances coverage of over 3,600 genes and the lab has also validated Illumina's HiSeq X Ten for its research pipeline.

Elaine Mardis, co-director of the Genome Institute at Washington University in St. Louis, discussed genomic testing for cancer in both clinical research and diagnosis.

The company plans to bring both tissue-based and blood-based targeted sequencing tests through FDA clearance.

Biologists turn to environmental DNA sampling to determine whether elusive or invasive species are shedding DNA in a given area.

Rob Knight writes at Scientific American that microbiome studies are about to break out of the laboratory.

Harold Varmus, the director of the National Cancer Institute, has announced that he is stepping down after nearly five years.

In Nature this week: omic analysis of permafrost microbes, hookworm genome, and more.